Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
|Articles|May 2, 2015
- BioPharm International-05-01-2015
- Volume 28
- Issue 5
Single-Use Biocontainer Increases Customizability
Meissner’s single-use biocontainer, FlexGro, is designed for use with rocker-style bioreactors.
Advertisement
Meissner’s single-use biocontainer, FlexGro, is designed for use with rocker-style bioreactors. The presterilized container is available with design options to accomodate up to 50 L and features Meissner’s TepoFlex polyethylene multi-layer film. TepoFlex is a clean film platform that does not have any slip agents ensuring consistency in the cell cultivation process.
A variety of connection, sampling options, and assembly designs allow the user to customize the biocontainer to fit specific end-user requirements. Different process needs can be met with a variety of available standard assembly designs.
Meissner
Articles in this issue
over 11 years ago
Biomanufacturing Outsourcing Globalization Continuesover 11 years ago
Ensuring the Quality of Biologicalsover 11 years ago
How to Stay Abreast of Shifting Regulations and Remain Compliantover 11 years ago
Filtration Technologies Advance to Meet Bioprocessing Needsover 11 years ago
Innovations and Adaptations in the Cold Chainover 11 years ago
An Update on the Quality Metrics Initiativeover 11 years ago
Streamlining Raw Materials Testingover 11 years ago
Best Practices in Facility Designover 11 years ago
Diaphragm Valve Streamlines InstallationAdvertisement
Related to this article
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study
5